CD40 and neoplasm: CD40 activation primes and expands T cell responses, while checkpoint blockade sustains T cell activity by preventing exhaustion (195–197).CD40 agonists are also being tested in combination with chemotherapy, which can provide a source of tumor-associated antigens (TAAs) via immunogenic cell death and enhance antigen cross-presentation (198).